Search Results for: log in

Gynecological Cancer Awareness Month

Gynecologic Cancer Awareness Month is an opportunity to raise awareness of the different types of cancers that originate in a woman’s reproductive organs.Each year, about 94,000 women are diagnosed with gynecologic cancer so it is important to understand the risk factors and possible symptoms along with available treatment options. All women are at risk for […]

Hematologic Cancers


Pathology Testing

Gestalt Diagnostics’ PathFlow Selected by BioReference Laboratories for Pathology Laboratory Business

SPOKANE, Wash., March 30, 2021 /PRNewswire/ — Gestalt Diagnostics today announced, that BioReference Laboratories Inc., an OPKO Health company, has selected their digital pathology solution, PathFlow®, to support its pathology business. PathFlow is an enterprise software platform specifically designed to bring the benefits of digital workflow to pathologists and pathology laboratories. Under the agreement, Gestalt is partnering […]


Reef Technology partners with Opko’s BioReference Labs for pop-up antibody testing sites

South Florida Business Journal With its latest partnership, Reef Technology has entered the Covid-19 antibody testing business following expansions of its ghost kitchen and last-mile delivery services. The Miami-based company, formerly ParkJockey, has partnered with BioReference Laboratories to launch pop-up testing sites across the nation, starting at the Miami International Mall. As opposed to testing efforts detecting who is […]

Coronavirus (COVID-19) Serology Events

In JAMA Oncology Publication, GeneDx Describes Lower Lifetime Risk of Gastric Cancer Conferred by CDH1

Updated Cancer Risk Estimates Will Allow For More Personalized Risk Assessment and Informed Decision Making For Patients with Rare Form of Hereditary Stomach Cancer GAITHERSBURG, Md., Aug. 06, 2019 (GLOBE NEWSWIRE) — GeneDx, Inc., a subsidiary of BioReference Laboratories, Inc.,  and a recognized leader in genetic and genomic testing, announced the results of a study […]

OPKO Health Announces Landmark Study Showing 4Kscore® Test is Strong Predictor of Prostate Cancer Mortality Published in European Urology

Study of 11,506 men shows that healthy men with an abnormal PSA and a low 4Kscore test result can be safely monitored rather than undergo prostate biopsy MIAMI, March 16, 2018 (GLOBE NEWSWIRE) —  OPKO Health, Inc.(NASDAQ:OPK) today announced that data from a landmark study of the 4Kscore® test entitled, “Twenty-year Risk of Prostate Cancer Death by Midlife Prostate-specific Antigen and a Panel […]